PMID: 2024961Feb 1, 1991

8-Aminoquinolines from Walter Reed Army Institute for Research for treatment and prophylaxis of Pneumocystis pneumonia in rat models

Antimicrobial Agents and Chemotherapy
M S BartlettJ W Smith

Abstract

Three 8-aminoquinolines from the Walter Reed Army Institute for Research (WRAIR), WR6026, WR238605, and WR242511, strongly inhibited Pneumocystis carinii growth in vitro at 1 microgram/ml. This activity was similar to that of primaquine. In rat therapy models, the WRAIR compounds affected Pneumocystis pneumonia at doses as low as 0.25 mg/kg (WR242511) or 0.5 mg/kg (WR6026 and WR238605). At these doses, primaquine alone was ineffective as therapy. In a rat prophylaxis model, all three WRAIR 8-aminoquinolines were extremely effective at daily doses of 0.57 mg/kg, showing activity greater than that of primaquine at this dosage and comparable to that of trimethoprim-sulfamethoxazole at 50/250 mg/kg.

References

Feb 1, 1992·Diagnostic Microbiology and Infectious Disease·M S BartlettJ W Smith
Sep 30, 2000·Bioorganic & Medicinal Chemistry Letters·T E GoodwinW A Tucker
Oct 6, 2009·Journal of Medicinal Chemistry·Nuno ValePaula Gomes
Apr 1, 1992·Antimicrobial Agents and Chemotherapy·M S BartlettJ W Smith
Oct 1, 1993·Antimicrobial Agents and Chemotherapy·S F QueenerJ W Smith
Apr 1, 1993·Antimicrobial Agents and Chemotherapy·A FournetJ Bruneton
Jul 1, 1993·Antimicrobial Agents and Chemotherapy·J A FishmanM S Bartlett
May 1, 1994·Antimicrobial Agents and Chemotherapy·G A Weinberg
Jul 29, 2006·The Journal of Pharmacy and Pharmacology·Tracy GarnierSimon L Croft
Dec 14, 2007·Bioorganic & Medicinal Chemistry Letters·Nuno ValePaula Gomes
Mar 21, 1998·The Journal of Eukaryotic Microbiology·M M ShawM S Bartlett
May 11, 1999·Journal of Acquired Immune Deficiency Syndromes : JAIDS·B G PettyR Hafner
Nov 1, 2006·Current Opinion in Infectious Diseases·Babu L Tekwani, Larry A Walker
Dec 24, 1992·The New England Journal of Medicine·H Masur

Related Concepts

WR 242511
Lung
August Rats
Pneumocystis Infections
Polychemotherapy
Primacin
Pneumocystis jiroveci
Dalacin C
WR6026
Pneumocystis Jiroveci Pneumonia

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.